ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
Q1FY27 revenue grew 26% to INR 2,150 Cr. Strategy focuses on US Generics volume growth, India Specialty therapeutic scale-up, and managing margin dilution from US branded investments.
Alembic Pharma delivered strong Q1 FY27 results with 26% revenue growth, driven by a 49% surge in US formulations. Strategy focuses on specialty US branded expansion and peptide development.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,150 Cr (+25.7% YoY) and net profit of ₹173.1 Cr (+12.1% YoY) for Q1 FY27.
Alembic Pharma delivered Q4 FY26 revenue of ₹1,838 Cr (up 4% YoY) and PAT of ₹203 Cr. FY26 revenue grew 10% YoY to ₹6,201 Cr with 25% EBITDA margins before R&D.
Management showcases a 100-year legacy transitioning into a high-tech global pharmaceutical player through massive facility expansion and R&D focus.
Alembic Pharma reported Q4FY26 revenue of INR 18.48 Bn, up 4% YoY, and PAT of INR 2.03 Bn, up 29% YoY. The company launched its first branded product, Pivya, in the US.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹1,848 Cr (+4.4% YoY) and net profit of ₹202.7 Cr (+29.2% YoY) for Q4 FY26.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹1,848 Cr (+4.4% YoY) and net profit of ₹201.5 Cr (+28.7% YoY) for Q4 FY26.